4.3 Article

Relationship between brain MRI lesion load and short-term disease evolution in non-disabling MS: a large-scale, multicentre study

Journal

MULTIPLE SCLEROSIS JOURNAL
Volume 17, Issue 3, Pages 319-326

Publisher

SAGE PUBLICATIONS LTD
DOI: 10.1177/1352458510388824

Keywords

benign; multiple sclerosis; disability; MRI; multicentre

Funding

  1. Teva Pharmaceutical Industries Ltd.
  2. Biogen-Dompe AG
  3. Italian MS Society
  4. Bayer Schering Pharma
  5. Merck Serono SA
  6. sanofi-aventis
  7. AstraZeneca
  8. Genentech, Inc.
  9. Novartis
  10. Biogen Idec
  11. Active Biotech
  12. European Charcot Foundation
  13. Lundbeck Inc.
  14. Talecris Biotherapeutics
  15. Roche
  16. UCB
  17. Wyeth
  18. MediciNova, Inc.
  19. Merck Serono
  20. GlaxoSmithKline
  21. NIH
  22. NIHR UCLH Comprehensive Biomedical Research Centre
  23. MS Society of Great Britain
  24. MS Society of Northern Ireland
  25. Teva Pharmaceutical Industries Ltd
  26. Almirall
  27. Eli Lilly and Company
  28. Genzyme Corporation
  29. Fundacio Esclerosi Multiple (FEM)
  30. Actelion Pharmaceuticals Ltd.
  31. Antisense Therapeutics Limited
  32. European Community (EEC)
  33. Dutch Multiple Sclerosis Society
  34. Genmab A/S
  35. Fondazione Italiana Sclerosi Multipla
  36. Fondazione Mariani

Ask authors/readers for more resources

Background and Objectives: We evaluated clinical and conventional MRI features of a large population of patients with non-disabling MS to identify potential markers of a benign disease course. Methods: In seven MAGNIMS centres we retrospectively identified 182 patients with benign (B) MS (EDSS score <= 3.0, disease duration >= 15 years) and 187 patients with non-disabling relapsing-remitting MS (NDRRMS) (Expanded Disability Status Scale score >= 3.0, disease duration between 5 and 14 years), in whom clinical data were collected within two weeks from a brain T2-weighted scan. Brain T2 lesion volume (LV) was measured in all patients. In 146 BMS and 146 NDRRMS patients, clinical data were also available after a median follow up of 29 months (range: 7-104 months). Results: Mean LV was higher in BMS than in NDRRMS patients (p < 0.001), but the mean ratio between LV and disease duration was higher in NDRRMS than in BMS patients (1.1 vs. 0.6 ml/year, p < 0.001). In BMS patients, brain LV was correlated with EDSS score increase at follow up (r=0.18, p=0.03). Conclusions: An overall low rate of brain LV increase during a long-lasting disease course might be a feature of BMS. In BMS patients, a high brain LV might be associated with worsening of locomotor disability at short-term follow up.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available